First Tracks Biotherapeutics Inc
TRAX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.62B
Close$
$6.45
85.9% downside
Current Fair Value
85.9% downsideOvervalued by 85.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.62 Billion |
|---|---|
| Enterprise Value | $1.45 Billion |
| Earnings per Share | $0 |
| Beta | 3.37 |
| Outstanding Shares | 35,390,679 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -13.33 |
|---|---|
| PEG | 45.5 |
| Price to Sales | - |
| Price to Book Ratio | 11.43 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.80
Consensus analyst estimateRevenue Estimate
$75.00 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.92
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.04%▼ 98.81% |
|---|---|
| Total Invested | $541,981▼ 99.92% |
| Investors Holding | 16▼ 137.00% |
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
104 employees
CEO: Daniel R. Faga
First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology firm focused on advancing antibody therapies. These innovative treatments are designed to modulate immune system pathways that contribute to autoimmune and inflammatory...